Survival following initiation of everolimus for 2nd-line treatment of metastatic renal cell carcinoma: prognostic factors in clinical practice and comparison to clinical trials
Publication
, Conference
Wong, MK; Jonasch, E; Pal, SK; Signorovitch, JE; Lin, PL; Liu, Z; Wang, X; Culver, K; Scott, JA; George, DJ; Vogelzang, NJ
Published in: BJU INTERNATIONAL
November 1, 2013
Duke Scholars
Published In
BJU INTERNATIONAL
EISSN
1464-410X
ISSN
1464-4096
Publication Date
November 1, 2013
Volume
112
Start / End Page
1 / 1
Location
Chicago, IL
Publisher
WILEY-BLACKWELL
Conference Name
12th International Kidney Cancer Symposium
Related Subject Headings
- Urology & Nephrology
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Wong, M. K., Jonasch, E., Pal, S. K., Signorovitch, J. E., Lin, P. L., Liu, Z., … Vogelzang, N. J. (2013). Survival following initiation of everolimus for 2nd-line treatment of metastatic renal cell carcinoma: prognostic factors in clinical practice and comparison to clinical trials. In BJU INTERNATIONAL (Vol. 112, pp. 1–1). Chicago, IL: WILEY-BLACKWELL.
Wong, M. K., E. Jonasch, S. K. Pal, J. E. Signorovitch, P. L. Lin, Z. Liu, X. Wang, et al. “Survival following initiation of everolimus for 2nd-line treatment of metastatic renal cell carcinoma: prognostic factors in clinical practice and comparison to clinical trials.” In BJU INTERNATIONAL, 112:1–1. WILEY-BLACKWELL, 2013.
Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Liu Z, et al. Survival following initiation of everolimus for 2nd-line treatment of metastatic renal cell carcinoma: prognostic factors in clinical practice and comparison to clinical trials. In: BJU INTERNATIONAL. WILEY-BLACKWELL; 2013. p. 1–1.
Wong, M. K., et al. “Survival following initiation of everolimus for 2nd-line treatment of metastatic renal cell carcinoma: prognostic factors in clinical practice and comparison to clinical trials.” BJU INTERNATIONAL, vol. 112, WILEY-BLACKWELL, 2013, pp. 1–1.
Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Liu Z, Wang X, Culver K, Scott JA, George DJ, Vogelzang NJ. Survival following initiation of everolimus for 2nd-line treatment of metastatic renal cell carcinoma: prognostic factors in clinical practice and comparison to clinical trials. BJU INTERNATIONAL. WILEY-BLACKWELL; 2013. p. 1–1.
Published In
BJU INTERNATIONAL
EISSN
1464-410X
ISSN
1464-4096
Publication Date
November 1, 2013
Volume
112
Start / End Page
1 / 1
Location
Chicago, IL
Publisher
WILEY-BLACKWELL
Conference Name
12th International Kidney Cancer Symposium
Related Subject Headings
- Urology & Nephrology
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1103 Clinical Sciences